ClinicalTrials.gg
Not yet recruitingNCT07951619SALVAGEUpdated Nov 20, 2026

Serplulimab Plus Bevacizumab and Chemotherapy for Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer After First-Line Anti-EGFR Therapy

A Phase 2 interventional study of Serplulimab and Bevacizumab in Colorectal Cancer (CRC) and Colorectal Adenocarcinoma, sponsored by China Medical University, China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by China Medical University, China · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 14 studies testing serplulimab in Colorectal Neoplasms — 13 open to participants now, 13 under way, 2 of them phase 3. serplulimab · Colorectal Neoplasms.

Planned enrollment
4th of 14
96 · median 52
Started
2026
with 5 others
Phase 2
11 of 14
10 open now
Primary completion
2028-06
later than 12 of 12 live
Registered
14th of 14
by date
Lead sponsor
1 of 14
China Medical University, China

Among the 14 studies testing serplulimab in Colorectal Neoplasms, this one is the 4th largest by planned enrollment, is one of 6 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 12 of the 12 other live ones, and was the 14th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,663 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

13 of the 14 studies testing serplulimab in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,177 Colorectal Neoplasms studies recruiting now, 760 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing serplulimab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized, controlled Phase 2 clinical study to evaluate the effectiveness and safety of adding serplulimab (an immunotherapy drug that targets PD-1) to standard second-line treatment with bevacizumab and chemotherapy. The study enrolls adult patients with advanced or metastatic, left-sided colorectal cancer whose tumors are microsatellite stable (MSS) or mismatch repair proficient (pMMR) and carry no mutations in the KRAS, NRAS, or BRAF genes (wild-type), and whose cancer worsened after first-line treatment containing an anti-EGFR antibody and chemotherapy.

Approximately 96 eligible participants will be randomly assigned in a 1:1 ratio to one of two treatment groups. Participants in the experimental group (Arm A) will receive serplulimab plus bevacizumab and chemotherapy every 3 weeks, while participants in the control group (Arm B) will receive bevacizumab and chemotherapy every 3 weeks. In both groups, the chemotherapy regimen is chosen based on prior first-line therapy: participants who previously received irinotecan will receive CapeOX (oxaliplatin and capecitabine), and those who previously received oxaliplatin will receive mXELIRI (irinotecan and capecitabine). Treatment will continue until disease progression, unacceptable side effects, withdrawal of consent, or study completion.

Read the detailed description

Scientific Rationale:Approximately 95% of patients with advanced or metastatic colorectal cancer (mCRC) harbor microsatellite stable (MSS) or mismatch repair-proficient (pMMR) tumors, a population in which single-agent immune checkpoint inhibitors have demonstrated minimal clinical activity. Preclinical and clinical evidence suggests that cytotoxic chemotherapy (by inducing immunogenic cell death and enhancing antigen presentation) and anti-angiogenic therapy such as bevacizumab (by promoting cytotoxic T-lymphocyte infiltration while reducing regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages) can reprogram the immunosuppressive tumor microenvironment and synergize with PD-1 blockade. Serplulimab (HLX10), a humanized anti-PD-1 IgG4 monoclonal antibody, combined with bevacizumab and XELOX previously demonstrated a substantial progression-free survival (PFS) improvement in first-line mCRC (ASTRUM-015 study). This study investigates whether adding serplulimab to standard second-line bevacizumab plus chemotherapy improves clinical outcomes specifically in patients with left-sided, RAS/BRAF wild-type, MSS/pMMR mCRC following disease progression on first-line anti-EGFR monoclonal antibody therapy.

03

Conditions studied

  • Colorectal Cancer (CRC)
  • Colorectal Adenocarcinoma

Keywords

  • Left-sided Colorectal Cancer
  • KRAS/NRAS/BRAF Wild-Type
  • MSS/pMMR
  • Second-Line Therapy
  • Serplulimab
  • Bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily agree to participate in the study and sign the written form.
  • confirmed left-sided, microsatellite stable (MSS) or mismatch repair-proficient (pMMR), KRAS/NRAS/BRAF wild-type advanced colorectal adenocarcinoma.
  • Disease progression following prior standard therapy (anti-EGFR monoclonal antibody combined with chemotherapy).
  • Aged >= 18 years, regardless of sex.
  • Expected survival >= 3 months.
  • (ECOG) performance status score of 0 or 1.
  • At least one measurable target lesion according to version 1.1 (RECIST v1.1).
  • Adequate hematologic function within 14 days prior to enrollment: >= 90 g/L (without blood transfusion within 14 days), >= 1.5 x 10\^9/L, and count >= 80 x 10\^9/L.
  • Adequate hepatic and renal function within 14 days prior to enrollment: total \<= 1.5 x (ULN); (ALT) and aspartate aminotransferase (AST) \<= 2.5 x ULN (or \<= 5 x ULN in patients with liver metastases); and endogenous >= 60 mL/min (calculated using the Cockcroft-Gault formula).
  • (LVEF) >= 50% as assessed by Doppler echocardiography.
  • Negative serum pregnancy test within 14 days prior to treatment initiation for women of ; eligible male and female patients of childbearing potential must agree to use reliable methods (hormonal methods, barrier methods, or abstinence) with their partners during the study and for at least 6 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in another interventional drug clinical trial (non-interventional clinical studies are permitted).
  • History of or concurrent other , except for cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the cervix or breast.
  • Known central nervous system (CNS) (for patients with clinically suspected , CT or MRI must be performed within 28 days prior to treatment initiation to exclude CNS metastases).
  • Clinically symptomatic pleural effusion or ascites requiring clinical intervention.
  • Current use of agents for any reason, or systemic therapy for immunosuppressive purposes (at a dose > 10 mg/day of prednisone or equivalent).
  • Presence of any active disease (including, but not limited to, autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, or nephritis).
  • History of organ transplantation.
  • Concurrent hyperthyroidism.
  • Concurrent vitiligo.
  • History of inflammatory bowel disease (such as ulcerative colitis or Crohn's disease) or chronic diarrheal diseases (such as irritable bowel syndrome).
  • History of sarcoidosis or tuberculosis.
  • Active , active , or (HIV) infection.
  • Newly diagnosed angina pectoris within 3 months prior to screening or myocardial infarction within 6 months prior to screening; cardiac arrhythmia (including >= 450 ms in males or >= 470 ms in females) requiring long-term antiarrhythmic medication; or (NYHA) Class >= II cardiac insufficiency.
  • Asthma requiring medical intervention with bronchodilators (patients with childhood asthma that has completely resolved and requires no intervention in adulthood may be included).
  • Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia, or other pulmonary inflammation requiring corticosteroid therapy.
  • History of psychotropic substance abuse with inability to abstain, or psychiatric disorders.
  • Urinalysis showing urine protein >= 2+ and 24-hour urinary protein quantification > 1.0 g.
  • Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.) or currently receiving thrombolytic or anticoagulant therapy.
  • Active bleeding or high risk of bleeding, such as significant bleeding tendency within 3 months prior to enrollment.
  • Other conditions judged by the investigator that may affect study results or lead to premature study discontinuation, such as substance abuse, severe illnesses (including psychiatric disorders such as epileptic seizures), or other medical, psychological, or social conditions that may compromise patient safety or compliance.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Arm A: Serplulimab Plus Bevacizumab and Chemotherapy

    Participants receive serplulimab (300 mg, Day 1) plus bevacizumab (7.5 mg/kg, Day 1) and chemotherapy every 3 weeks (Q3W). The chemotherapy regimen is determined by prior first-line therapy: participants previously treated with an irinotecan-containing regimen receive CapeOX (oxaliplatin 130 mg/m2 on Day 1 plus capecitabine 1000 mg/m2 on Days 1-14, Q3W), while those previously treated with an oxaliplatin-containing regimen receive mXELIRI (irinotecan 200 mg/m2 on Day 1 plus capecitabine 800 mg/m2 on Days 1-14, Q3W). Local antitumor therapy (such as radiotherapy or radiofrequency ablation) for localized metastases is permitted. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

    Drug: Serplulimab · Drug: Bevacizumab · Drug: Oxaliplatin · Drug: irinotecan · Drug: Capecitabine

  • Active comparator
    Arm B: Bevacizumab Plus Chemotherapy

    Participants receive bevacizumab (7.5 mg/kg, Day 1) plus chemotherapy every 3 weeks (Q3W). The chemotherapy regimen is determined by prior first-line therapy: participants previously treated with an irinotecan-containing regimen receive CapeOX (oxaliplatin 130 mg/m2 on Day 1 plus capecitabine 1000 mg/m2 on Days 1-14, Q3W), while those previously treated with an oxaliplatin-containing regimen receive mXELIRI (irinotecan 200 mg/m2 on Day 1 plus capecitabine 800 mg/m2 on Days 1-14, Q3W). Local antitumor therapy (such as radiotherapy or radiofrequency ablation) for localized metastases is permitted. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

    Drug: Bevacizumab · Drug: Oxaliplatin · Drug: irinotecan · Drug: Capecitabine

Interventions

  • Serplulimab (HLX10, Hansizhuang; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a fixed dose of 300 mg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

    Also known as: HLX10, Hansizhuang

  • Bevacizumab (Hanbeitai; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a dose of 7.5 mg/kg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

  • Administered as part of the CapeOX regimen only to participants who previously received an irinotecan-containing first-line regimen. Oxaliplatin is given at a dose of 130 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

  • Administered as part of the mXELIRI regimen only to participants who previously received an oxaliplatin-containing first-line therapy. Irinotecan is given at a dose of 200 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

  • Administered on Days 1 to 14 of each 21-day (3-week) cycle, with the dose determined by the chemotherapy backbone assigned based on prior first-line therapy: In the CapeOX regimen (for participants previously treated with an irinotecan-containing regimen): 1000 mg/m2 on Days 1-14, every 3 weeks. In the mXELIRI regimen (for participants previously treated with an oxaliplatin-containing regimen): 800 mg/m2 on Days 1-14, every 3 weeks. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. 9-Month Progression-Free Survival (PFS) Rate

    The proportion of participants who are alive and free of radiographic disease progression at 9 months after the initiation of study treatment. Tumor assessments are performed at baseline and every 6 weeks (±7 days) during treatment using contrast-enhanced CT or MRI according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

    Time frame: At 9 months after treatment initiation

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Defined as the time from the initiation of study treatment to the first documented disease progression (evaluated by investigators according to RECIST v1.1) or death from any cause, whichever occurs first, estimated using the Kaplan-Meier method. Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

    Time frame: From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

  2. Objective Response Rate (ORR)

    The percentage of participants achieving a complete response (CR) or partial response (PR) as their best overall response, evaluated by investigators according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

    Time frame: From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

  3. Disease Control Rate (DCR)

    The percentage of participants achieving a complete response (CR), partial response (PR), or stable disease (SD) as their best overall response, evaluated by investigators according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

    Time frame: From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

  4. Overall Survival (OS)

    Defined as the time from enrollment to death from any cause, estimated using the Kaplan-Meier method. Participants who are still alive at the last follow-up will be censored at the date of last known survival.

    Time frame: From enrollment until death from any cause, assessed every 3 months during the first year after treatment discontinuation and every 6 months thereafter up to study completion (approximately 24 months)

  5. Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs), as well as clinically significant changes in laboratory tests, vital signs, 12-lead electrocardiograms, and echocardiograms. Toxicity severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).

    Time frame: From signing of informed consent through 30 days after the last dose of study treatment (or until initiation of new antitumor therapy, whichever occurs first)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

Of 498 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 75. This study's planned 18 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951619
Lead sponsor
China Medical University, China
Responsible party
Jingdong Zhang (Chief Physician, Professor, Liaoning Cancer Hospital & Institute) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Qian Dong, Doctor
Contact
dongqian08@163.com
17309815028

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion